ABSTRACT
No disponible
Subject(s)
Clonidine/therapeutic use , Aspirin/therapeutic use , Coronary Thrombosis/complications , Stress, Physiological , /methods , Cerebrovascular Disorders/epidemiology , Indicators of Morbidity and Mortality , Risk FactorsSubject(s)
Adrenergic alpha-2 Receptor Agonists/therapeutic use , Aspirin/therapeutic use , Clonidine/therapeutic use , Myocardial Infarction/prevention & control , Perioperative Care/methods , Platelet Aggregation Inhibitors/therapeutic use , Postoperative Complications/prevention & control , Surgical Procedures, Operative , Thromboembolism/prevention & control , Aged , Aged, 80 and over , Aspirin/adverse effects , Cardiovascular Diseases/complications , Cardiovascular Diseases/drug therapy , Double-Blind Method , Hospital Mortality , Humans , Middle Aged , Myocardial Infarction/etiology , Myocardial Infarction/mortality , Platelet Aggregation Inhibitors/adverse effects , Postoperative Complications/etiology , Postoperative Complications/mortality , Postoperative Hemorrhage/chemically induced , Postoperative Hemorrhage/epidemiology , Premedication , Secondary Prevention , Thromboembolism/etiologyABSTRACT
Positron emission tomography (PET) is useful for evaluating the cardiac metabolism of free fatty acid, glucose and oxygen both in human clinical practice and in experimental animal models. However, no data are available for such an evaluation in a model of stable compensated left ventricular hypertrophy in 14-month-old spontaneously hypertensive rats (SHRs). This study was designed to assess the metabolism of myocardial glucose in SHRs using 2-deoxy-2-[18F]fluoro-D-glucose ((18)F-FDG) using PET. The study was performed on 14-month-old male SHRs (n = 4) and age-matched Wistar Kyoto (WKY) rats (n = 4). PET scans were performed after the administration of anaesthesia with isoflurane and injection of a bolus of 39.37 ± 3.25 (mean ± SD) MBq (1.06 mCi) of (18)F-FDG. The standardized uptake value (SUV) was used to evaluate (18)F-FDG uptake by the heart. The analysis of SUV showed increased metabolism in the left ventricle of SHRs compared with WKY rats. Our results show that small animal PET using (18)F-FDG can be performed in 14-month-old SHRs to evaluate new therapies in the regression of left ventricular hypertrophy in SHRs because pathological myocardial metabolism in the SHR differs from the normal metabolism of the WKY rat.
Subject(s)
Glucose/metabolism , Myocardium/metabolism , Positron-Emission Tomography/veterinary , Rats, Inbred SHR/metabolism , Rats, Inbred WKY/metabolism , Animals , Fluorodeoxyglucose F18 , Male , Positron-Emission Tomography/methods , RatsABSTRACT
No disponible
Subject(s)
Humans , Troponin T , Troponin T/isolation & purification , Vascular Diseases/diagnosis , Thoracic Surgery/methods , Cohort Studies , Ischemia/diagnosis , Prospective Studies , Trinitrotoluene , Thoracic Surgical Procedures/standards , Thoracic Surgical Procedures/trendsSubject(s)
Postoperative Complications/blood , Postoperative Complications/mortality , Surgical Procedures, Operative/mortality , Troponin T/blood , Vascular Diseases/blood , Vascular Diseases/mortality , Cohort Studies , Humans , Postoperative Complications/etiology , Time Factors , Vascular Diseases/etiologyABSTRACT
Debido a la alta prevalencia y mortalidad de las complicacionescardíacas en los pacientes que se someten acirugía no cardíaca se han puesto en marcha diferentesestrategias para disminuirla entre las que se encuentranla utilización perioperatoria de los bloqueantes de losreceptores beta adrenérgicos. Su efecto beneficioso frentea la isquemia miocárdica es multifactorial: mejoran elbalance de oxígeno miocárdico, protegen de la rupturade la placa de ateroma y disminuyen la vasoconstriccióncoronaria. Recientemente se han publicado diferentestrabajos que confirman este efecto beneficioso con unabaja incidencia de efectos secundarios, que nosotrosresumimos en este artículo
A variety of strategies have been used to reduce thehigh prevalence and mortality rates of cardiac complicationsin patients undergoing noncardiac surgery. Oneapproach taken is to prescribe agents that block Beta-adrenergicreceptors. The effect of Beta-blockers on myocardialischemia is multifactorial: they correct myocardial oxygenimbalance, prevent rupture of atheromatous plaque,and reduce coronary vasoconstriction. We summarize theresults of several recently published studies that confirmthe beneficial effects and the low incidence of side effects
Subject(s)
Aged , Humans , Adrenergic beta-Antagonists/therapeutic use , Heart Diseases/prevention & control , Postoperative Complications/prevention & control , Preanesthetic Medication , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/adverse effects , Adrenergic beta-Antagonists , Adrenergic beta-Antagonists/pharmacology , Arrhythmias, Cardiac/drug therapy , Arrhythmias, Cardiac/prevention & control , Arteriosclerosis/drug therapy , Evidence-Based Medicine , Hemodynamics , Intraoperative Care/methods , Intraoperative Complications/prevention & control , Myocardial Ischemia/drug therapy , Patient Selection , Postoperative Care/methods , Risk Management , Rupture, Spontaneous , Surgical Procedures, OperativeABSTRACT
A variety of strategies have been used to reduce the high prevalence and mortality rates of cardiac complications in patients undergoing noncardiac surgery. One approach taken is to prescribe agents that block beta-adrenergic receptors. The effect of beta-blockers on myocardial ischemia is multifactorial: they correct myocardial oxygen imbalance, prevent rupture of atheromatous plaque, and reduce coronary vasoconstriction. We summarize the results of several recently published studies that confirm the beneficial effects and the low incidence of side effects.
